Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara

Cancer Immunology, Immunotherapy

Volumn 55, Issue 1, 2006, Pages 39-46

  Mackova, Jana ^a   Stasikova, Jana ^a   Kutinova, Luda ^a   Masin, Jiri ^b   Hainz, Petr ^a   Simsova, Marcela ^b   Gabriel, Pavel ^a   Sebo, Peter ^b   Nemeckova, Sarka ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

Bordetella adenylate cyclase; HPV E7; MVA; Vaccine; Vaccinia virus

Indexed keywords

ADENYLATE CYCLASE TOXIN; CARRIER PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PROTEIN E7; TUMOR VACCINE; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; BORDETELLA; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; GENETIC TRANSDUCTION; GRAM NEGATIVE BACTERIUM; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNOSTIMULATION; MODIFIED VACCINIA VIRUS ANKARA; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR; TUMOR IMMUNITY; VACCINATION; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ADENYLATE CYCLASE TOXIN; ANIMALS; ANTIGENS, NEOPLASM; ANTIGENS, VIRAL; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; FEMALE; HUMAN PAPILLOMAVIRUS 16; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; TUMOR CELLS, CULTURED; VACCINIA VIRUS;

EID: 28944446238     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0700-7     Document Type: Article

References (25)

1. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Ling M, Wu TC (2001) Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J Clin Invest 108:669-678
2. Chu NR, Wu HB, Wu T, Boux LJ, Siegel MI, Mizzen LA (2000) Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121:216-225
3. El-Azami El-Idrissi M, Ladant D, Leclerc C (2002) The adenylate cyclase of Bordetella pertussis: a vector to target antigen presenting cells. Toxicon 40:1661-1665
4. El-Azami El-Idrissi M, Bauche C, Loucka J, Osicka R, Sebo P, Ladant D, Leclerc C (2003) Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18: Role of toxin acylation and identification of the main integrin interaction domain. J Biol Chem 278:38514-38521
5. Fayolle C, Osickova A, Osicka R, Henry T, Rojas MJ, Saron MF, Sebo P, Leclerc C (2001) Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity. J Virol 75:7330-7338
6. Fayolle C, Sebo P, Ladant D, Ullmann A, Leclerc C (1996) In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying viral CD8+ T-cell epitopes. J Immunol 156:4697-4706
7. Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 4:46-54
8. Greenstone HL, Nieland JD, de Visser KE, De Bruijn ML, Kirnbauer R, Roden RB, Lowy DR, Kast WM, Schiller JT (1998) Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805
9. Guermonprez P, Khelef N, Blouin E, Rieu P, Ricciardi-Castagnoli P, Guiso N, Ladant D, Leclerc C (2001) The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J Exp Med 193:1035-1044
10. Hanke T, Blanchard TJ, Schneider J, Hannan CM, Becker M, Gilbert SC, Hill AV, Smith GL, McMichael A (1998) Enhancement of MHC class I-restricted peptide-specific T-cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16:439-445
11. Hodge JW, Poole DJ, Aarts WM, Gomez YA, Gritz L, Schlom J (2003) Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses. Cancer Res 63:7942-7949
12. Joklik WK (1962) The purification of four strains of poxvirus. Virology 18:9-18
13. Lee SJ, Gray MC, Guo L, Sebo P, Hewlett EL (1999) Epitope mapping of monoclonal antibodies against Bordetella pertussis adenylate cyclase toxin. Infect Immun 67:2090-2095
14. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, Wu TC (1996) Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 56:21-26
15. Loucka J, Schlecht G, Vodolanova J, Leclerc C, ebo P (2002) Delivery of a MalE CD4(+)-T-cell epitope into the major histocompatibility complex class II antigen presentation pathway by Bordetella pertussis adenylate cyclase. Infect Immun 70:1002-1005
16. Mackova J, Kutinova L, Hainz P, Krystofova J, Sroller V, Otahal P, Gabriel P, Nemeckova S (2004) Adjuvant effect of dendritic cells transduced with recombinant vaccinia virus expressing HPV16-E7 is inhibited by co-expression of IL12. Int J Oncol 24:1581-1588
17. Mayr A, Danner K (1978) Vaccination against pox diseases under immunosuppressive conditions. Dev Biol Stand 41:225-234
18. Nakagawa M, Viscidi R, Deshmukh I, Costa MD, Palefsky JM, Farhat S, Moscicki AB (2002) Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol 9:877-882
19. Osicka R, Osickova A, Basar T, Guermonprez P, Rojas M, Leclerc C, Sebo P (2000) Delivery of CD8(+) T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase: delineation of cell invasive structures and permissive insertion sites. Infect Immun 68:247-256
20. Pumpens P, Razanskas R, Pushko P, Renhof R, Gusars I, Skrastina D, Ose V, Borisova G, Sominskaya I, Petrovskis I, Jansons J, Sasnauskas K (2002) Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes. Intervirology 45:24-32
21. Schlecht G, Loucka J, Najar H, Sebo P, Leclerc C (2004) Antigen targeting to CD11b allows efficient presentation of CD4+ and CD8+ T-cell epitopes and in vivo Th1-polarized T-cell priming. J Immunol 173:6089-6097
22. Simsova M, Sebo P, Leclerc C (2004) The adenylate cyclase toxin from Bordetella pertussis-a novel promising vehicle for antigen delivery to dendritic cells. Int J Med Microbiol 293:571-573
23. Sutter G, Staib C (2003) Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3:263-271
24. von Knebel-Doeberitz, Oltersdorf T, Schwarz E, Gissmann L (1988) Correlation of modified human papilloma virus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Res 48:3780-3786
25. zurHausen H (1999) Papillomaviruses in human cancers. Proc Assoc Am Physicians 111:581-587